Design principles for orally bioavailable drugs

被引：162

作者：

Navia, MA

Chaturvedi, PR

机构：

[1] Vertex Pharmaceuticals Inc., Cambridge, MA 02139-4211

来源：

DRUG DISCOVERY TODAY | 1996年 / 1卷 / 05期

关键词：

D O I：

10.1016/1359-6446(96)10020-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Compound design is the hallmark of modern pharmaceutical research and development. Unfortunately, comprehensive and reliable guidelines for the introduction of favorable bioavailability properties into designed compounds remain elusive. Here, the authors discuss the limited set of design principles that address the problem of bioavailability, based on a retrospective analysis of orally bioavailable drugs. The roles of partition coefficient, molecular weight, carrier-mediated transport and conformational flexibility are evaluated. These properties are discussed as guiding principles only, and cannot be considered ail-encompassing determinants of oral bioavailability.

引用

收藏

页码：179 / 189

页数：11

相关论文

共 57 条

[11] INTESTINAL-ABSORPTION MECHANISM OF DIPEPTIDE ANGIOTENSIN CONVERTING ENZYME-INHIBITORS OF THE LYSYL-PROLINE TYPE - LISINOPRIL AND SQ-29,852 [J].

FRIEDMAN, DI ;

AMIDON, GL .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (12) :995-998

[12]

Gibaldi M. P., 1982, PHARMACOKINETICS

[13]

Gilman AG, 1990, GOODMAN GILMANS PHAR

[14] HEPATIC PROCESSING OF CHOLECYSTOKININ PEPTIDES .2. CELLULAR-METABOLISM, TRANSPORT, AND BILIARY-EXCRETION [J].

GORES, GJ ;

MILLER, LJ ;

LARUSSO, NF .

AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 250 (03) :G350-G356

[15] X-RAY STRUCTURE OF CALCINEURIN INHIBITED BY THE IMMUNOPHILIN IMMUNOSUPPRESSANT FKBP12-FK506 COMPLEX [J].

GRIFFITH, JP ;

KIM, JL ;

KIM, EE ;

SINTCHAK, MD ;

THOMSON, JA ;

FITZGIBBON, MJ ;

FLEMING, MA ;

CARON, PR ;

HSIAO, K ;

NAVIA, MA .

CELL, 1995, 82 (03) :507-522

[16] EVALUATION OF PHYSICOCHEMICAL PARAMETERS IMPORTANT TO THE ORAL BIOAVAILABILITY OF PEPTIDE-LIKE COMPOUNDS - IMPLICATIONS FOR THE SYNTHESIS OF RENIN INHIBITORS [J].

HAMILTON, HW ;

STEINBAUGH, BA ;

STEWART, BH ;

CHAN, OH ;

SCHMID, HL ;

SCHROEDER, R ;

RYAN, MJ ;

KEISER, J ;

TAYLOR, MD ;

BLANKLEY, CJ ;

KALTENBRONN, JS ;

WRIGHT, J ;

HICKS, J .

JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (09) :1446-1455

[17] PEPTIDES AND RELATED DRUGS - A REVIEW OF THEIR ABSORPTION, METABOLISM, AND EXCRETION [J].

HUMPHREY, MJ ;

RINGROSE, PS .

DRUG METABOLISM REVIEWS, 1986, 17 (3-4) :283-310

[18] PHYSICOCHEMICAL DETERMINANTS IN HEPATIC EXTRACTION OF SMALL PEPTIDES [J].

HUNTER, EB ;

POWERS, SP ;

KOST, LJ ;

PINON, DI ;

MILLER, LJ ;

LARUSSO, NF .

HEPATOLOGY, 1990, 12 (01) :76-82

[19] CONFORMATION OF FK506 IN X-RAY STRUCTURES OF ITS COMPLEXES WITH HUMAN RECOMBINANT FKBP12 MUTANTS [J].

ITOH, S ;

DECENZO, MT ;

LIVINGSTON, DJ ;

PEARLMAN, DA ;

NAVIA, MA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (17) :1983-1988

[20] STRUCTURE COMPARISON OF NATIVE AND MUTANT HUMAN RECOMBINANT FKBP12 COMPLEXES WITH THE IMMUNOSUPPRESSANT DRUG FK506 (TACROLIMUS) [J].

ITOH, S ;

NAVIA, MA .

PROTEIN SCIENCE, 1995, 4 (11) :2261-2268

← 1 2 3 4 5 6 →